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Combination therapy with warfarin plus
clopidogrel improves outcomes in femoropopliteal
bypass surgery patients
Mario Monaco, MD,a Luigi Di Tommaso, MD,b Giovanni Battista Pinna, MD,b Stefano Lillo, MD,a
Vincenzo Schiavone, MD,a and Paolo Stassano, MD,b Castel Volturno (CE) and Naples, Italy
Background: Patients having undergone femoropopliteal bypass surgery remain at significant risk of graft failure.
Although antithrombotic therapy is of paramount importance in these patients, the effect of oral anticoagulation therapy
(OAT) on outcomes remains unresolved.We performed a randomized, prospective study to assess the impact of OAT plus
clopidogrel vs dual antiplatelet therapy on peripheral vascular and systemic cardiovascular outcomes in patients who had
undergone femoropopliteal bypass surgery.
Methods: Three hundred forty-one patients who had undergone femoropopliteal surgery were enrolled and randomized:
173 patients received clopidogrel 75 mg/d plus OAT with warfarin (C  OAT), and 168 patients received dual
antiplatelet therapy with clopidogrel 75 mg/d plus aspirin 100 mg/d (C  acetylsalicylic acid [ASA]). Study end points
were graft patency and the occurrence of severe peripheral arterial ischemia, and the incidence of bleeding episodes.
Results: Follow-up ranged from 4 to 9 years. The graft patency rate and the freedom from severe peripheral arterial
ischemia was significantly higher in COAT group than in CASA group (P .026 and .044, respectively, Cox-Mantel
test). The linearized incidence of minor bleeding complications was significantly higher in C  OAT group than in C 
ASA group (2.85% patient-years vs 1.37% patient-years; P  .03). The incidence of major adverse cardiovascular events,
including mortality, was found to be similar (P  .34) for both study groups.
Conclusions: In patients who have undergone femoropopliteal vascular surgery, combination therapy with clopidogrel
plus warfarin is more effective than dual antiplatelet therapy in increasing graft patency and in reducing severe peripheral
ischemia. These improvements are obtained at the expenses of an increase in the rate of minor anticoagulation-related
complications. ( J Vasc Surg 2012;56:96-105.)
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pPatients having undergone femoropopliteal bypass sur-
gery remain at significant risk of graft failure, despite a
careful surgical technique.1-3 In the first year after opera-
tion, the incidence of graft occlusion is as high as 28% to
45% and the treatment with antithrombotic agents seems
to impact favorably on postoperative results.4-6 Moreover,
in patients with peripheral arterial disease the risk of myo-
cardial infarction, stroke, or death from cardiovascular
causes is three times as high as for persons without periph-
eral arterial disease.7,8 Many studies evaluated the efficacy
of antiplatelet therapy in maintaining vascular patency in
various categories of patients, and while the evidence for a
benefit of antiplatelet therapy after prosthetic femoropop-
liteal bypass surgery is widely accepted, to date, the benefit
for autogenous saphenous vein graft is not clearly demon-
strated.9-11 However, there is general agreement that anti-
platelet therapy is of paramount importance in these pa-
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96ients to improve the results and to prevent atherosclerotic
omplications.12
The effect of long-term oral anticoagulation therapy
OAT) on early and long-term outcome after femoropop-
iteal arterial reconstruction remains unresolved.13,14 Re-
ently, the Warfarin Antiplatelet Vascular Evaluation
WAVE) randomized trial reported that the combination
f an oral anticoagulant plus an antiplatelet drug was not
ore effective than antiplatelet therapy alone in preventing
ajor cardiovascular events, and further, it was associated
ith an increased life-threatening risk of bleeding.15 Other
tudies have demonstrated that in high-risk patients oral
nticoagulant plus antiplatelet therapy appears to be more
ffective than antiplatelet-only therapy in reducing the risk
f graft occlusion.4,16,17
Clopidogrel, an adenosine diphosphate receptor antago-
ist that inhibits platelet activation, has shown in clinical
ractice a favorable benefit/risk ratio in preventing cardiovas-
ular events,18 although there is no general agreement on its
fficacy in stable patients and in long-term therapy.19,20
To date, no study has been carried out to determine the
fficacy of combination therapy with oral anticoagulant and
lopidogrel on peripheral vascular patients.
We have performed a randomized, prospective study
ith the aim of assessing the early and long-term impact of
ral anticoagulant plus clopidogrel therapy vs dual anti-
latelet (clopidogrel plus aspirin) therapy on peripheral
ascular and on systemic cardiovascular outcomes in a
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Volume 56, Number 1 Monaco et al 97consecutive series of peripheral vascular patients who had
undergone femoropopliteal bypass surgery.
METHODS
Study design. The present study was an open-label
randomized trial. It was conducted at two centers perform-
ing cardiovascular surgery in Italy, was approved by the
ethics review boards of both participating institutions, and
all patients provided written informed consent.
From January 2002 to December 2006, all patients
with atherosclerotic lesions of the lower extremities and in
need of femoropopliteal surgery were enrolled (Fig 1).
Preoperatively, all patients underwent digital subtraction
angiography (DSA) of abdominal aorta and lower extrem-
ities. Furthermore, an ultrasonic echo-Doppler scan of
lower extremity arteries, abdominal aorta and iliac axis, and
the ankle-brachial pressure index (ABPI) by Doppler
method at rest were obtained in all enrolled patients.
Indication to femoropopliteal bypass surgery was ob-
jective evidence of peripheral arterial disease (occlusion or
stenosis 75%) with intermittent claudication, ischemic
pain at rest, nonhealing ulcers or focal gangrene, previous
amputation, arterial revascularization, and the blue toe
syndrome.
Patients were considered to be at high risk for graft
Fig 1. Consort diagram for the study flow.CASA, C
clopidogrel plus oral anticoagulation therapy patients; Ofailure, according to DSA evaluation, in the presence of [oor arterial runoff, defined as occlusion of one of the tibial
rteries or diffuse disease in both tibial arteries with multi-
le sites of 50% stenoses, in the presence of occlusion or
iffuse disease of the peroneal artery, and/or redo femoro-
opliteal bypass grafting. Patients with only peroneal artery
atency were not included in the study population, because
hey are not comparable to patients with at least one tibial
rtery patency, due to the relative importance of the per-
neal artery on runoff bed.21
During the study period, 430 consecutive patients were
dmitted for elective femoropopliteal bypass surgery. Pa-
ients were excluded if there were other indications for
AT, atrial fibrillation or mechanical cardiac prosthesis (59
atients, 13.7%), they had active bleeding (eight patients,
.9%), had a stroke within 6 months before enrollment (12
atients, 2.8%), or required dialysis (10 patients, 2.3%). A
otal of 341 patients met criteria for inclusion; randomiza-
ion to the type of procedure was made after the patient was
eemed eligible, and each patient was assigned to either
roup by the last digit of his or her hospital admission
umber. In total, 173 patients received clopidogrel 75
g/d plus OAT with warfarin (COAT group), and 168
atients received dual antiplatelet therapy with clopidogrel
5 mg/d plus aspirin 100 mg/d (C  acetylsalicylic acid
grel plus acetylsalicylic acid therapy patients;COAT,
ral anticoagulation therapy.lopidoASA] group).
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July 201298 Monaco et alIn the present study, we decided to use a low-intensity
regimen of anticoagulation, maintaining the INR value
between 2.0 and 2.5. By the light of medical literature
tendency to use a low-medium intensity of anticoagulation
(INR 1.5-3-0) in a variety of clinical settings, such as atrial
fibrillation, mechanical cardiac prosthesis, and deep venous
thrombosis prophylaxis,22-24 we hypothesized that also in
peripheral vascular patients, a low-medium intensity INR
range will be effective and safer than standard INR range.
From the second postoperative day, all patients in both
groups received enoxaparin (1 mg/kg/d), which was with-
drawn in C  OAT patients when the target INR was
reached and at the fourth postoperative day for C  ASA
patients. Both therapeutic regimens (C  OAT and C 
ASA) were started on the second postoperative day.
Preoperatively, all patients underwent preoperative pe-
ripheral angiography of abdominal aorta and lower extrem-
ities. Furthermore, an ultrasonic echo-Doppler scan of
lower extremity arteries, abdominal aorta and iliac axis, and
the ABPI by Doppler method at rest were obtained in all
enrolled patients.
The arterial bypass grafting was done with either gen-
eral balanced or epidural anesthesia. The bypass grafts were
constructed in all enrolled patients with knitted gelatin- or
collagen-coated Dacron prosthesis (Gelsoft; Vascutek,
Inchinnan, Scotland, UK, or Intergard;Maquet Cardiovas-
cular, Restatt, Germany) for above-knee (AK) site of distal
anastomosis and with internal saphenous vein, in a reversed
fashion, for below-knee (BK) outflow site. All patients
underwent systemic anticoagulation with heparin (1 mg/
kg) intravenously before arterial occlusion, maintaining an
activated clotting time above 250 seconds. The bypass
grafts were constructed with standard surgical techniques,
and arteriography was done at completion of the bypass
grafting procedure to assess its technical adequacy. Antico-
agulation therapy with heparin was not reversed at the
completion of the procedure. We decided to include in the
present study only prosthetic AK and autogenous BK fem-
oropopliteal bypass to obtain a strong uniformity of popu-
lation, so that we will be able to maintain a strict adherence
to study protocol during the entire enrollment period at the
two study centers, avoiding confusion. Moreover, while for
BK outflow site there is no doubt that the saphenous vein
represents the first choice,2 many studies have addressed
the good results with AK prosthetic Dacron bypass as a
simple and straightforward procedure.25,26
Study end points and definitions. Coprimary study
end points were graft patency, defined as an ABPI  0.9
with a duplex ultrasound graft scan examination that
showed velocities of more than 30 cm/s and 150 cm/s,
and the absence of severe peripheral arterial ischemia
threatening the viability of the limb and leading to ampu-
tation. Primary patency rate, primary-assisted patency rate,
and secondary patency rate were defined according to the
Sarac study.16 Primary and primary-assisted graft patency
rates were included in the analysis, while secondary graft
patency was considered as graft failure: the incidence of life-
threatening, moderate, or minor bleeding episodes. Life- ehreatening bleeding was defined as fatal or intracranial
leeding or bleeding requiring hospitalization and transfu-
ion of more than 2 units of blood or fresh-frozen plasma.
oderate bleeding was defined as intraocular hemorrhage
r as bleeding requiring hospitalization and transfusion of
2 units of blood or blood products. All other bleeding,
ot requiring hospitalization and/or transfusion, was clas-
ified as minor.
Secondary end point was the occurrence of any major
dverse cardiovascular event (MACE), such as myocardial
nfarction, stroke, severe ischemia of the coronary arteries
eading to urgent intervention, or death from cardiovascu-
ar causes. Death from cardiovascular causes was defined as
ny death for which there was no clearly documented
oncardiovascular cause. Myocardial infarction was defined
s the presence of diagnostic electrocardiographic changes
nd/or elevation of the level of serum creatine kinase MB
raction, or serum troponin (3  normal value). Stroke,
oth ischemic or hemorrhagic, was defined as a new focal
eurologic deficit lasting more than 24 hours and docu-
ented by a computed tomographic or magnetic reso-
ance imaging scan. Severe coronary ischemia was defined
s unstable angina with electrocardiographic changes re-
uiring hospitalization and coronary revascularization.
Follow-up. Patients were followed up for a minimum
f 4 years and for a maximum of 9 years. Follow-up data, at
0 days if a patient had been discharged from the hospital
nd every 4 months thereafter, were obtained directly from
he patients in the outpatient clinic and/or their family
hysician by telephone call or by written questionnaire.
nformation on events, other hospitalizations, and adher-
nce to the assigned treatment regimen was achieved. INR
alues were checked every month or more frequently, as
ppropriate. All patients underwent ultrasonic echo-
oppler scan evaluation, including rest ABPI, every 6
onths.
Variables. The preoperative variables tested for their
ssociation with outcome included age, gender, urgent
peration, ABPI, high risk for graft failure, AK synthetic
raft, BK vein graft, left ventricular ejection fraction, New
orkHeart Association (NYHA) class, hepatic dysfunction,
efined as abnormal prothrombin activity (65%) and
erum transaminases level ( two normal value), serum
reatinine level, presence of diabetes, coexistent coronary
rtery disease, previous myocardial infarction, and previous
erebrovascular accident.
Statistical analysis. All variables are presented as
ean and standard deviation of the mean. Student t test for
npaired data, 2, or Fisher exact test were used, as appro-
riate. Two-tailed tests of significance are reported, and P
alues less than .05 were considered statistically significant.
Intention-to-treat analyses provided information about
vents from the time of randomization. If more than one
nd point occurred within the follow-up period, only the
rst event was considered.
Patients could experience more than one end point if
hey suffered different discrete end points. If more than one
nd point occurred within the follow-up period, then the
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limb salvage rates, and incidence of MACEs, including
survival, were compared with the Kaplan-Meier analysis,
using the long-rank test (Cox-Mantel) to ascertain differ-
ences between groups. The rate of bleeding was calculated
with linearized rates expressed as events/100 patient-years
of follow-up and reported with a 95% confidence interval
(CI). The likelihood-ratio test was used to compare the
linearized rates between the two study groups.
Logistic regression analysis and the Cox proportional
hazards regression model were used to analyze the factors
associated to primary end points (graft patency rate and
bleeding episode incidence). Linearity assumption for con-
tinuous variables was assessed by checking the significance
of the transformed variable added to the model. Trans-
forming was achieved by taking the natural logarithm and
the square of the variable. Proportional hazard assumption
was met in all models. When the linearity of the variable age
was not met, the final Cox model included both the linear
and the square term of this variable.27 Among patients
receiving oral anticoagulation, the time in the therapeutic
range was calculated by the linear-interpolation method
described by Rosendaal.28
In a systematic review of antiplatelet therapy random-
ized controlled trials,4 a median incidence of 30% of graft
occlusion was reported, at a median of 2.0 years after
randomization. Therefore, our study enrolled a total sam-
ple 340 patients to observe a 20% reduction, ie, 24%
incidence of long-term graft failure, with a statistical power
80% (1- error level) to detect a probability of .05 (
error level). All data were analyzed using STATISTICA 6.0
(StatSoft Inc, Tulsa, Okla).
RESULTS
Early and 30-day outcome. There were no differ-
ences between the two groups studied in age, sex, and
comorbidities (Table I). Operative data and perioperative
and 30-day outcomes are shown in Table II. Fourteen
patients (0.4%) necessitated a surgical perioperative revi-
sion for significant bleeding: eight on COAT and six on
Table I. Demographics and comorbidities
C 
n
Mean age (y, mean 	 SD) 68.4
Sex (male), n (%) 116
Hypertension, n (%) 135
Coronary artery disease, n (%) 110
Diabetes mellitus, n (%) 78
COPD, n (%) 48
Currently smoking, n (%) 38
Renal insufficiency (Cr 1.7), n (%) 53
High risk for graft failure, n (%) 41
C ASA, Patients who underwent therapy with aspirin and clopidogrel; C
chronic obstructive pulmonary disease; Cr, creatinine, expressed in mg/dL
aSignificant .05 with 2 test.CASA (P .8). Early reintervention for primary-assisted 1atency was required in eight patients, four in each study
roup (2.3% in C  OAT group and 2.4% in C  ASA
roup; P .8). In all cases, after intraprocedural angiogra-
hy to detect the site (inflow and/or outflow) to treat, an
ngioplasty was performed trimming the ends of grafts to
orm an enlarged lumen. Only one perioperative death
ccurred, in the COAT group (0.6%; P .5 vs C ASA
roup), and the overall 30-day mortality was three patients
0.88%, 2 in C  OAT vs 1 in C  ASA patients; P  .5).
he incidence of all 30-day complications, either peripher-
l-arterial-related or MACEs, the length of hospital stay
LOS), and the number of packed red blood cells trans-
used were not different in either group (Table II). The
0-day primary or primary-assisted graft patency was
igher, although not statistically significant, for the C 
AT group than for the C ASA group (98.2% vs 93.7%;
 .07, odds ratio [OR] 0.27, 95%CI 1.1-6.5), while
he median ABPI was similar in both groups (0.93 	 0.14
n C  OAT vs 0.91 	 0.16; P  .3).
At multivariate analysis, the only causes influencing the
oprimary study end points were urgent operation (P 
01, exp (B)  0.17, 95% CI  0.04-0.67), high risk for
raft occlusion (P  .002, exp (B)  0.23, 95% CI 
.09-0.57), and hepatic dysfunction (P  .006, exp (B) 
.06, 95% CI  1.01-1.61).
Long-term outcome. Mean duration of follow-up
as 6.39	 1.6 years (median, 6.6 years) and included 161
atients for the C  OAT group and 157 patients for the
 ASA group: 94.1% and 93.4%, respectively. Among
atients receiving oral anticoagulation, the mean INR was
.2; of interest is that 86.0% of the time, the INR values
ere in the therapeutic range (2.0-2.5), while in 9.2% of
he time, they were below 2.0, and finally 4.8% of the time,
hey were above 2.5.28
The linearized rate of bleeding at follow-up is reported
n Table III. The overall incidence rates of life-threatening
r moderate anticoagulation therapy-related complications
considered together because either required transfusion
nd/or hospitalization) were similar in the two study
roups (1.78% patient-years in the C  OAT group and
C ASA
n 168 P valuea
.4 66.2 	 14.2 .14
0) 122 (72.6) .15
1) 140 (83.3) .17
6) 97 (57.7) .25
1) 84 (50.0) .35
7) 53 (31.5) .42
5) 45 (26.8) .25
6) 40 (23.8) .22
7) 37 (22.0) .81
T, patients who underwent therapy with warfarin and clopidogrel; COPD,OAT
173
	 12
(67.
(78.
(63.
(45.
(27.
(18.
(30.
(23.
 OA.62% patient-years in the C  ASA group; P  .7), while
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complications, not requiring transfusion and/or hospital-
ization, was significantly higher in the C  OAT group
than in the C  ASA group (2.85% patient-years vs 1.37%
patient-years; P  .03). Patients with minor bleeding
stopped their therapy for few days (generally not more than
1 week) and then restarted the same therapy: this subgroup
of 35 patients (24 in C  OAT group and 11 in C  ASA
group) did not show a significant difference in freedom of
graft failure compared with all patient data: at 5-year fol-
low-up, freedom of graft failure was 70.8% 	 2.7% (C 
OAT) and 54.4% 	 3.9% (C  ASA), P  .53 and .56,
respectively, vs all patient incidence.
At Kaplan-Meier analysis, the incidence of MACEs, in-
cluding mortality, was found to be similar (P .34) for both
study groups (Fig 2), while the 3-, 5-, and 8-year overall graft
patency rates were significantly higher in the COAT group
compared with the C  ASA group (86.7% 	 2.7% vs
80.8%	3.2%; 77.3%	3.5% vs 63.3%	4.1%; 44.4%	7.2%
vs 30.4%	 5.9%, respectively;P .026, Cox-Mantel test; Fig
3). Primary and primary-assisted graft patencies are depicted
in Fig 4 for both treatment groups. Although the study was
not conceived to analyze a prespecified subgroup of patients,
the combination therapy shows the greatest difference in poor
Table II. Operative data and early (perioperative and 30
Mortality, n (%)
Myocardial infarction, n
Respiratory (pneumonia), n
Hemorrhagic, n (%)
Wound hematoma n
Gastrointestinal, n
Central nervous system, n
Genitourinary, n
Bypass graft data
Femoropopliteal AK, n (%)
Femoropopliteal BK, n (%)
Graft failure, n (%)
In high risk patients, n (%)
MACEs, n (%)
LOS days, mean 	 SD
Packed red blood cells units, mean 	 SD
AK, Above-knee; BK, below-knee; C ASA, patients who underwent thera
warfarin and clopidogrel; LOS, length of hospital stay; MACEs, major adver
Table III. Linearized rate of bleeding at follow-up
C 
%/pat
Bleeding 39 4
Life-threatening/requiring hospitalization and/or
transfusion 15 1
Not requiring hospitalization and/or transfusion 24 2
C ASA, Patients who underwent therapy with aspirin and clopidogrel; Carterial runoff patients: at 5-year follow-up there was 56.1%	 c.3% vs 29.7% 	 3.5% freedom from graft failure in the C 
AT and C ASA groups, respectively (P .03, OR 3.0,
5% CI  1.07-8.63), and at same follow-up time the graft
atency rate for all patients was significantly higher than for
oor runoff patients (P .01 and .001, in the COAT and
 ASA groups, respectively). Long-term primary-assisted
atency was obtained whenever possible by endovascular pro-
edure (percutaneous transluminal angioplasty at the site of
tenosis) or by bypass revision, when percutaneous translumi-
al angioplasty was not effective or technically suitable. The
reatment (coumadin plus antiplatelet or double antiplatelet)
as not changed.
The rate of freedom from severe peripheral arterial isch-
mia leading to amputation was significantly higher in C 
AT than in C  ASA patients (96.7% 	1.4% vs 92.2% 	
.3%; 94.2% 	 2.0% vs 84.8% 	 3.1%; 77.6% 	 5.3% vs 63.
%	 6.1%, respectively; P .044, Cox-Mantel test; Fig 5).
With Cox analysis of any causes, age, preoperative
BPI, poor arterial runoff, urgent operation, and presence
f diabetes were predictive of graft failure, while only age,
rgent operation, and presence of diabetes were predictive
f bleeding episode incidence (Table IV). The presence of
n AK synthetic or of a BK vein graft did not influence the
s) morbidity and mortality rates
OAT
173
C ASA
n  168 P value
1.2) 1 (0.6) .50
1
0
5.8) 11 (6.5) .94
5 3 .37
2 3 .48
1 .49
3 4 .48
63.6) 111 (70.2) .26
36.4) 47 (29.7) .26
2.3) 10 (5.9) .07
50.0) 6 (60.0) .10
1.7) 5 (2.9) .34
1.9 6.5 	 2.2 .38
0.7 0.5 	 0.6 .17
h aspirin and clopidogrel; C OAT, patients who underwent therapy with
diovascular events.
(n  161) C ASA(n  157)
P value
patients
ear (95% CI)
No of patients
%/patient-year (95% CI)
3.89-5.37) 24 2.99 ( 2.38-3.06) .06
1.32-2.24) 13 1.62 (1.17-2.07) .7
2.27-3.43) 11 1.37 (0.95-1.78) .03
, patients who underwent therapy with warfarin and clopidogrel.day
C 
n 
2 (
1
1
10 (
—
110 (
63 (
4 (
2 (
3 (
6.3 	
0.4 	
py witOAT
No of
ient-y
.63 (
.78 (
.85 (oprimary end points.
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Volume 56, Number 1 Monaco et al 101Fig 2. Freedom from graft failure for the two study groups. C  ASA, Clopidogrel plus acetylsalicylic acid therapy
patients; C  OAT, clopidogrel plus oral anticoagulation therapy patients.Fig 3. Freedom from major adverse cardiovascular events, including mortality, for the two study groups. C 
ASA, Clopidogrel plus acetylsalicylic acid therapy patients; C  OAT, clopidogrel plus oral anticoagulation
therapy patients.
JOURNAL OF VASCULAR SURGERY
July 2012102 Monaco et alFig 4. Freedom from primary graft failure for the two study groups. C  ASA, Clopidogrel plus acetylsalicylic acid
therapy patients; C  OAT, clopidogrel plus oral anticoagulation therapy patients.Fig 5. Freedom from amputation for the two study groups. C  ASA, Clopidogrel plus acetylsalicylic acid therapy
patients; C  OAT, clopidogrel plus oral anticoagulation therapy patients.
e
T
e
t
p
i
g
4
r
s
t
p
a
t
d
a
g
c
h
s
b
d
p
p
s
a
w
k
K
r
a
t
p
m
y
t
p
i
e
i
JOURNAL OF VASCULAR SURGERY
Volume 56, Number 1 Monaco et al 103DISCUSSION
The present study shows that, in patients who have
undergone surgical femoropopliteal revascularization,
clopidogrel plus warfarin combination therapy is more ef-
fective than dual antiplatelet therapy in increasing graft
patency and in curbing the rate of severe limb ischemia
requiring amputation. These beneficial effects are obtained
with an increase in the rate of minor anticoagulation-
related complications not requiring transfusion or hospital-
ization.
Our results compare favorably with previous studies in
which long-term anticoagulation therapy with warfarin
plus ASA in patients with arterial reconstruction for limb
salvage improved the patency rate of femoropopliteal by-
pass graft.16,29,30 Rosenthal, in a post hoc analysis, demon-
strated that a subgroup of patients at high risk for graft
failure was the one most likely to benefit from long-term
anticoagulation therapy.31 More recently, Jackson, in a
multicenter randomized trial, demonstrated that combina-
tion therapy with warfarin plus ASA improved the patency
rate only of prosthetic femoropopliteal bypass graft, but not
of femoropopliteal vein grafts.32
The long-term anticoagulation therapy for patients
with severe peripheral vascular disease is not without risk:
the yearly cumulative incidence rate of hemorrhagic com-
plications from long-term warfarin use ranges between 3%
and 12%.33 The Dutch Bypass Oral Anticoagulants or
Aspirin Study showed an incidence of 2.9 hemorrhagic
events per 100 patient-years.34 The WAVE trial15 has re-
cently confirmed these results, reporting a 4% incidence of
life-threatening bleeding in patients receiving a combina-
tion therapy (anticoagulant plus antiplatelet) compared
with 1.2% in patients receiving antiplatelet therapy alone
(RR 3.41; P  .001), while not preventing major cardio-
vascular complications. These findings are consistent with
our data: while the incidence of MACEs, including mortal-
ity, on early and long-term outcomes was similar in the two
study groups, we indeed found a significant improvement
in peripheral arterial outcome at the expense of an increase
in minor bleeding episodes. This difference could be ex-
plained by the use of clopidogrel as an antiplatelet drug and
by the maintenance of a nonaggressive anticoagulation
regimen (INR 2.0-2.5). Clopidogrel provides a substantial
Table IV. Cox hazards regression: independent predictors
Predictors
Graft failure
P value Exp (B)
Age .001 0.59
Age2 .0006 0.35
Urgent operation .0001 2.87
Preoperative ABPI .0001 3.25
Diabetes .0001 2.42
Poor arterial run-off .0001 1.08
ABPI, Ankle-brachial pressure index.
All tested variables are listed in the text.increase in quality-adjusted life expectancy for patients with tither peripheral arterial disease or a recent stroke.18,35-39
his favorable pharmacologic regimen, both in terms of
fficacy and safety, may reduce the risks of a combination
herapy with warfarin (at reduced dosage) andmay improve
eripheral arterial disease-related outcomes.
The anticoagulation intensity for the prevention of
schemic events in patients after femoropopliteal bypass
raft surgery is usually obtained with an INR of 3.0 to
.0.33 Our results with a lower and narrower INR value
ange seem to be equally safe and effective in preventing
uch ischemic events.
Preoperative ABPI, despite the increasing sophistica-
ion of vascular surgical practice and its apparent simplicity,
lays a key role in the assessment of symptomatic peripheral
rtery disease patients and in the management of therapeu-
ic regimens.40,41 In our patients, low preoperative ABPI
id not influence early outcomes, while it was significantly
ssociated with worse outcome at follow-up. The 30-day
raft patency was higher, although not statistically signifi-
ant, for C  OAT patients and only urgent operation,
igh risk for graft occlusion and hepatic dysfunction were
ignificantly associated to coprimary end points.
We evaluated all patients in need of femoropopliteal
ypass surgery and, despite the study design, we did not
etect outcome differences between low- and high-risk
atients; the presence of poor arterial runoff (about 25% of
atients in our series) significantly influences graft occlu-
ion rate, at early and long-term outcome. Moreover, to
void a possible confounding factor, we excluded patients
ith renal function impairment requiring dialysis, a well-
nown risk factor for graft failure. Interestingly, in the
aplan-Meier analysis, graft patency and limb salvage rates
each the highest difference between the two study groups
round the 5- to 6-year follow-up and tend to maintain
his difference up to the end of follow-up time. In these
atients the combination therapy (C  OAT) seems to be
ost effective in the late years of follow-up, while in the first
ears of follow-up, it shows an efficacy comparable with
hat of dual antiplatelet therapy. This effect may be ex-
lained by age, which at multivariate analysis, negatively
mpacts long-term outcomes. In fact, we observed that the
ffect of age on survival is nonlinear, as documented by the
nclusion of the square term in the model, showing that
ong-term graft failure and of bleeding rate
Bleeding rate
% CI P value Exp (B) 95% CI
4-0.79 .02 0.61 0.40-0.92
3-0.68 .001 2.98 1.68-5.27
1-4.55 .005 0.09 0.01-0.58
5-4.87 .15 1.43 0.88-2.33
8-3.78 .01 1.65 1.11-2.64
4-1.12 .22 0.84 0.68-1.10of l
95
0.4
0.2
1.8
2.1
1.5
1.0he worsening of peripheral arterial disease between ages 70
11
1
1
1
1
1
1
1
1
2
2
JOURNAL OF VASCULAR SURGERY
July 2012104 Monaco et aland 75 is much greater than that between ages 60 and 65.
However, in spite of age effect, our results suggest that
long-term anticoagulation therapy with warfarin and clopi-
dogrel, besides improving graft patency rates, has also a
favorable impact in preventing vascular events, by limiting
the progressive occlusion of diseased arteries.
Study limitations. It could be useful to consider the
quality of life outcomes, given the consistent risk of ampu-
tation in femoropopliteal bypass surgery patients and the
need of having frequent blood tests for patients on antico-
agulation therapy. The monitoring and hospitalization
costs, also, were not determined, and this might be an
important limitation of our study. Another limitation could
be the lack of blinding of investigators, which is inherent in
the trial design, and the lack of an independent event-
adjudication committee. However, we believe that the
open-label randomized study design, appropriately pow-
ered cohort, choice of end points such as graft patency,
severe peripheral arterial ischemia, and incidence of bleed-
ing episodes helps in minimizing this limitation.
Implications. Combination therapy of clopidogrel
plus warfarin is more effective than dual antiplatelet therapy
in increasing graft patency in patients with femoropopliteal
arterial vascular surgery. This effect will not necessarily
translate into better long-term secondary prevention of
major cardiovascular events compared with antiplatelet
therapy. The advantages of such a combination therapy
may call for larger, multicenter trials to thoroughly investi-
gate this important clinical issue.
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